GPCR135: A Potential Drug Target and Biomarker (G51289)

Target Name: RXFP3

NCBI ID: G51289

RXFP3

GPCR135: A Potential Drug Target and Biomarker

G-protein coupled receptor GPCR135 (RXFP3) is a protein that plays a crucial role in cellular signaling. It is a member of the GPCR family, which is a large superfamily of transmembrane proteins that regulate a wide range of cellular processes. GPCR135 is expressed in many different tissues and cells, including the brain, heart, and peripheral tissues.

GPCR135 is a potential drug target because of its involvement in a variety of cellular signaling pathways. For example, GPCR135 has been shown to play a role in the regulation of pain perception, anxiety, and depression. It is also involved in the regulation of inflammation, and has been shown to contribute to the development of various diseases, including cancer.

In addition to its potential as a drug target, GPCR135 is also a potential biomarker. The ability to detect and measure the expression of GPCR135 could be used to monitor the effectiveness of various therapeutic approaches. For example, if a drug is shown to increase the expression of GPCR135, this could be an indication that the drug is having its intended effect.

GPCR135 is also of interest because of its structure. The GPCR family of proteins is characterized by a specific protein-ligand interaction that allows for the regulation of a wide range of cellular processes. GPCR135 is no exception to this rule, and has been shown to interact with a variety of different ligands.

One of the most interesting aspects of GPCR135 is its role in the regulation of pain perception. GPCR135 is known to play a role in the regulation of pain signaling pathways, and has been shown to contribute to the development of pain conditions such as neuropathic pain and chronic pain.

In addition to its involvement in pain regulation, GPCR135 is also involved in the regulation of anxiety and depression. Studies have shown that GPCR135 is involved in the regulation of anxiety and depression-related behaviors, and that it may be a potential target for interventions aimed at treating these conditions.

GPCR135 is also of interest because of its potential role in the regulation of inflammation. The immune system is involved in the regulation of inflammation, and GPCR135 is known to play a role in this process. Studies have shown that GPCR135 is involved in the regulation of inflammation-related signaling pathways, and that it may be a potential target for interventions aimed at reducing inflammation.

In conclusion, GPCR135 is a protein that has the potential to be a drug target or biomarker. Its involvement in a variety of cellular signaling pathways, including pain, anxiety, and depression, makes it an attractive target for therapeutic intervention. Its structure, which allows for the regulation by a variety of different ligands, also adds to its potential as a drug or biomarker. Further research is needed to fully understand the role of GPCR135 in cellular signaling and its potential as a therapeutic intervention.

Protein Name: Relaxin Family Peptide Receptor 3

Functions: Receptor for RNL3/relaxin-3. Binding of the ligand inhibit cAMP accumulation

The "RXFP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RXFP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets